Sammour Y, Nassif M, Magwire M, et al. - Since two classes of glucose-lowering medications (SGLT-2Is and GLP-1RAs) have recently been shown to significantly improve cardiovascular outcomes, researchers retrospectively assessed the safety and effectiveness of GLP-1RAs and SGLT-2Is in patients undergoing orthotopic heart transplant at a high-volume center. They observed substantial weight loss, decrease in insulin use, HbA1c, and low-density lipoprotein-cholesterol among 21 patients. In addition, both SGLT-2Is and GLP-1RAs were well tolerated with no adverse effects contributing to either therapy discontinuation. Although larger studies of patients after solid organ transplant are required, this small hypothesis-generating study shows that SGLT-2Is and GLP-1RAs seem safe and effective therapies among patients with T2D after heart transplant.